Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Executive Summary

Janssen plans a February launch for Risperdal following FDA's Dec. 29 approval of the dopamine/serotonin antagonist. Risperdal (risperidone) was approved for the treatment of psychotic disorders 20.5 months from the date the J&J subsidiary submitted the NDA ("The Pink Sheet" Jan. 3, p. 14). The antipsychotic received a "1P" rating, designating a new molecular entity receiving a priority review.

You may also be interested in...

Risperdal Consta Priced Aggressively; J&J Sets High Premium To Zyprexa

Johnson & Johnson's Risperdal Consta (risperidone) is being launched at approximately twice the daily cost of Lilly's market-leading antipsychotic Zyprexa (olanzapine)

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts